Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
https://doi.org/10.17650/1818-8346-2009-0-1-21-28
Abstract
Peripheral neuropathy is one of the most common complications of Bortezomib treatment. In this article you can find a brief literature review and single center experience: we estimated the prevalence of neuropathy development and it’s characteristics in a group of 33 patients. Peripheral neuropathy was found in 16 (48.5%) patients. In this group initial manifestations of neurotoxicity (grade I and II) were found in 8 (50%) patients. Advanced neuropathy (grade III and IV) was found in 6 (37.5%) and 2 (12.5%) patients respectively. In the majority of patients neuropathy was reversible if Bortezomibe dose was modified and symptomatic treatment was administered at the proper time.
About the Authors
N. V. Stepanova
St.-Petersburg State Pavlov Medical University
Russian Federation
Russian Federation
E. R. Machulaitene
St.-Petersburg State Pavlov Medical University
Russian Federation
Russian Federation
G. N. Salogub
St.-Petersburg State Pavlov Medical University
Russian Federation
Russian Federation
E. V. Melnikova
St.-Petersburg State Pavlov Medical University
Russian Federation
Russian Federation
References
1. Richardson P.G., Barlogie B., Berenson J. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348(26):2609—17.
2. Jagannath S., Barlogie B., Berenson J. et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127(2):165—72.
3. Durie B.G.M., Kyle R., Belch A. et al. Myeloma management guidelines. Hematol J 2003;4:379—98.
4. Cancer therapy evaluation program. Common terminology criteria for adverse events, version 3. http://ctep.cancer.gov
5. Boccadoro M., Marmont F., Tribalto M. et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991;9:444—8.
6. Borrello I., Ferguson A., Huff C.A. et al. Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma. Efficacy and neurotoxicity. ASH Annual Meeting Abstracts. Blood 2006;108:abstr 3528.
7. Chaudhry V., Cornblath D.R., Corse A. et al. Thalidomide-induced neuropathy. Neurology 2002;59(12):1872—5.
8. Rooper A.H., Gorson K.C. Neuropaties associated with paraproteinemia. N Engl J Med 1998;338 (22):1601—9.
9. Badros A., Goloubeva O., Dalal J.S. et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110(5):1042—9.
10. Cavaletti G., Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 2007;92(10):1308—10.
11. Gupta S., Pagliuca A., Devereux S. et al. Life-threatening motor neurotoxicity in association with bortezomib. Haematologica 2006;91(7):1001.
12. Гринберг Д.А., Аминофф М.Д., Саймо Р.П. Клиническая неврология. М.: Медэкспресс-информ, 2004. с. 282—314.
13. Jagannath S., Richardson P.G., Briemberg H. et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24(19):3113—20.
14. Caravita T., Petrucci M.T., Spagnoli A. et al. Neuropathy in multiple myeloma patients treated with bortezomib: a multicenter experience. ASH Annual Meeting Abstracts. Blood 2007;110:abstr 4823.
15. Бессмельцев С.С., Карягина Е.В., Стельмашенко Л.В. и др. Частота, характеристика и методы лечения периферической нейропатии у больных множественной миеломой, получавших бортезомиб (велкейд). Онкогематология 2008;3:52—62.
16. Levine S., Saltzman A. Pyridoxine (vitamin B6) toxicity: enhancement by uremia in rats. Food Chem Toxicol 2002;40(10):1449—51.
17. Teoh G., Tan D., Hwang W. et al. Use of immunoglobulin infusions in the management of bortezomib-induced peripheral neuropathy in multiple myeloma. ASH Annual Meeting Abstracts. Blood 2006;108:abstr 5097.
18. Catley L., Anderson K.C. Velcade and vitamin C: too much of a good thing? Clin Cancer Res 2006;12(1):3—4.
Review
For citations:
Stepanova N.V., Machulaitene E.R., Salogub G.N., Melnikova E.V. Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review. Oncohematology. 2009;(1):21-28. (In Russ.) https://doi.org/10.17650/1818-8346-2009-0-1-21-28
Views:
254
Email this article 